Autonomix Medical (AMIX) Q4 2025 earnings summary

Executive summary

• Amendment No. 1 to the annual report was filed to include Part III information previously omitted, covering directors, executive officers, compensation, security ownership, related transactions, and principal accounting fees.

• The amendment does not update disclosures from the original 10-K and should be read in conjunction with it.

Significant events and developments

• The company corrected an error in previously issued financial statements, triggering a review of incentive-based compensation recovery.

• The company is not a shell company and is listed on Nasdaq under the symbol AMIX.

• As of July 23, 2025, there were 5,049,887 shares of common stock outstanding.

Capital allocation and financing

• Aggregate market value of voting equity held by non-affiliates as of the last business day of the most recent second fiscal quarter was $8,113,215.

• In September 2023, a private placement for up to $2.0 million in convertible notes was commenced, with $500,000 purchased by management, directors, and a family member.

• On IPO closing, convertible notes converted into common stock at $40.00 per share.